Company ViroGates A/S

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Bio Diagnostics & Testing

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:52 2024-04-26 am EDT			5-day change	1st Jan Change
6.5 ^DKK	-11.92%		+8.33%	+7.97%

Apr. 15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI
Mar. 21	ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

Number of employees: 10

DKK in Million	2022	Weight	2023	Weight	Delta
Prognostic Tool 100.0 %	10	100.0 %	6	100.0 %	-45.01%

DKK in Million	2022	Weight	2023	Weight	Delta
Denmark 100.0 %	10	100.0 %	6	100.0 %	-45.01%

Managers	Title	Age	Since
Jesper Eugen-Olsen FOU	Founder	61	00-12-31
Jakob Knudsen CEO	Chief Executive Officer	56	11-03-31
Josephine Baum Jørgensen DFI	Director of Finance/CFO	33	23-02-28
David Stig Wülser SAM	Sales & Marketing	-	-
May Britt Dyvelkov AUD	Comptroller/Controller/Auditor	64	08-10-31
Thomas Krarup SAM	Sales & Marketing	61	18-02-28

Members of the board	Title	Age	Since
Lars Krogsgaard BRD	Director/Board Member	57	16-03-31
Patrik Olof Dahlén CHM	Chairman	62	22-03-31
Lars Kongsbak BRD	Director/Board Member	63	15-01-31
Valérie Soulier BRD	Director/Board Member	57	22-03-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,447,554	4,690,654 ( 72.75 %)	2,585 ( 0.0401 %)	72.75 %

Name	Equities	%	Valuation
Niels Peter Louis-Hansen 24.79 %	1,598,150	24.79 %	2 M kr
Kim Erik Poul Ginnerup 10.63 %	685,330	10.63 %	646 239 kr
Lars Krogsgaard 10.63 %	685,264	10.63 %	646 177 kr
Aetas Healthcare ApS 5.955 %	383,941	5.955 %	362 041 kr
Jesper Eugen-Olsen 4.048 %	260,976	4.048 %	246 090 kr
Jakob Knudsen 1.947 %	125,514	1.947 %	118 355 kr
Thomas Krarup 0.2500 %	16,116	0.2500 %	15 197 kr
Patrik Olof Dahlén 0.1639 %	10,570	0.1639 %	9 967 kr
Lars Kongsbak 0.1081 %	6,968	0.1081 %	6 571 kr
VIROGATES A/S 0.0401 %	2,585	0.0401 %	2 438 kr

Name	Equities	%	Valuation
VIROGATES A/S 0.04%	2,585	0.04%	2,438 $

ViroGates A/S

Banevænget 13

3460, Birkerod

+45 21 13 13 36

http://www.virogates.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Diagnostics & Testing

	1st Jan change	Capi.
VIROGATES A/S	+7.97%	6.84M
EXACT SCIENCES CORPORATION	-19.71%	10.67B
IOVANCE BIOTHERAPEUTICS, INC.	+43.30%	3.22B
GUARDANT HEALTH, INC.	-35.66%	2.09B
BGI GENOMICS CO., LTD.	-17.21%	2.04B
VERACYTE, INC.	-28.86%	1.46B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+18.70%	1B
SEEGENE, INC.	-4.37%	734M
CAREDX, INC	-36.51%	391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-47.24%	379M

Bio Diagnostics & Testing